Rigel Pharmaceuticals, Inc. (RIGL) Key Metrics
RIGL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $858.7M
- Enterprise value
- $856.6M
- P/E (TTM)
- 2.7
- Forward P/E
- 9.3
- PEG ratio
- —
- Price / sales
- 3.1 10-yr median 4.2
- Price / book
- 2.1 10-yr median 5.8
- EV / EBITDA
- 9.1
- Dividend yield
- —
- Beta
- 1.19
RIGL key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRIGL valuation Price multiples at each fiscal year-end price.
RIGL returns How much profit the business earns on the capital it uses.
RIGL per-share figures Results divided by the shares outstanding at year-end.
RIGL financial health Debt, liquidity and how easily interest is covered.
RIGL efficiency & capital use Working capital cycle and where the cash goes.
RIGL valuation history
RIGL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RIGL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RIGL cash returned to shareholders
RIGL price vs earnings per share
RIGL key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $806.9M | $297.5M | $252.3M | $258.6M | $451.8M | $590.6M | $358.2M | $369.2M | $490.1M | $224.6M |
| Enterprise value | $705.3M | $280.1M | $256.0M | $242.0M | $357.4M | $572.4M | $296.5M | $240.7M | $374.7M | $153.3M |
| P/E ratio | 2.2 | 17.0 | — | — | — | — | — | — | — | — |
| Price / sales | 2.7 | 1.7 | 2.2 | 2.2 | 3.0 | 5.4 | 6.0 | 8.3 | 109.3 | 11.0 |
| Price / book | 2.1 | 90.5 | — | — | 14.9 | 17.4 | 6.7 | 3.4 | 4.9 | 4.1 |
| Price / free cash flow | 10.7 | 9.6 | — | — | 86.0 | — | — | — | — | — |
| Price / operating cash flow | 10.7 | 9.5 | — | — | 76.9 | — | — | — | — | — |
| EV / sales | 2.4 | 1.6 | 2.2 | 2.0 | 2.4 | 5.3 | 5.0 | 5.4 | 83.6 | 7.5 |
| EV / EBITDA | 5.4 | 9.8 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 9.3 | 9.0 | — | — | 68.1 | — | — | — | — | — |
| Earnings yield | 45.5% | 5.9% | −9.9% | −22.6% | −4.0% | −5.0% | −18.6% | −19.1% | −15.9% | −30.8% |
| Free cash flow yield | 9.4% | 10.4% | −8.2% | −28.7% | 1.2% | −9.0% | −12.0% | −16.2% | −15.9% | −34.1% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.0% | 3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $42.83 | $16.82 | $14.50 | $15.00 | $26.50 | $35.00 | $21.40 | $23.00 | $38.80 | $23.80 |
| Per share | ||||||||||
| Revenue per share | $15.62 | $10.14 | $6.72 | $6.97 | $8.75 | $6.44 | $3.54 | $2.77 | $0.35 | $2.16 |
| Earnings per share | $19.48 | $0.99 | −$1.44 | −$3.40 | −$1.05 | −$1.76 | −$3.98 | −$4.39 | −$6.17 | −$7.33 |
| Operating cash flow per share | $4.02 | $1.78 | −$0.33 | −$4.28 | $0.34 | −$3.09 | −$2.48 | −$3.66 | −$6.14 | −$8.04 |
| Free cash flow per share | $4.02 | $1.76 | −$1.19 | −$4.30 | $0.31 | −$3.17 | −$2.57 | −$3.73 | −$6.15 | −$8.13 |
| Cash per share | $8.22 | $4.37 | $3.27 | $3.38 | $7.33 | $3.40 | $5.86 | $8.01 | $9.16 | $7.92 |
| Book value per share | $20.78 | $0.19 | −$1.65 | −$0.79 | $1.78 | $2.02 | $3.21 | $6.84 | $7.97 | $5.83 |
| Tangible book value per share | $19.47 | −$1.35 | −$2.44 | −$1.66 | $1.78 | $2.02 | $3.21 | $6.84 | $7.97 | $5.83 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.02 | $0.86 | $0.03 | $0.04 | $0.07 | $0.09 | $0.07 | $0.01 | $0.09 |
| Debt per share | $2.83 | $3.39 | $3.48 | $2.41 | $1.79 | $2.32 | $2.17 | — | $0.02 | $0.37 |
| Shares outstanding | 18.8M | 17.7M | 17.4M | 17.2M | 17.0M | 16.9M | 16.7M | 16.1M | 12.6M | 9.4M |
| Change in shares outstanding | +6.5% | +1.6% | +0.9% | +1.1% | +1.0% | +0.8% | +4.3% | +27.1% | +33.8% | +6.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 185.9% | — | — | — | −55.6% | −67.7% | −81.3% | −67.0% | −100.2% | −94.6% |
| Return on invested capital (ROIC) | 91.0% | — | — | — | — | −584.3% | — | — | — | — |
| Return on assets (ROA) | 108.3% | 12.4% | −20.0% | −38.8% | −12.9% | −23.1% | −46.4% | −54.6% | −79.1% | −66.0% |
| Return on tangible assets | 75.1% | 12.8% | −24.3% | −49.1% | −10.7% | −26.9% | −45.1% | −50.7% | −65.5% | −88.6% |
| Free cash flow margin | 25.7% | 17.3% | −17.7% | −61.7% | 3.5% | −49.2% | −72.5% | −134.7% | — | −376.3% |
| Income quality (OCF / net income) | 0.21 | 1.80 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $53.3M | $60.0M | $60.6M | $41.6M | $30.6M | $39.1M | $36.3M | — | $284,000 | $3.5M |
| Cash & short-term investments | $155.0M | $77.3M | $56.9M | $58.2M | $125.0M | $57.3M | $98.1M | $128.5M | $115.8M | $74.8M |
| Net debt | −$101.7M | −$17.4M | $3.6M | −$16.7M | −$94.4M | −$18.2M | −$61.8M | −$128.5M | −$115.5M | −$71.3M |
| Debt / equity | 0.14 | 18.24 | — | — | 1.01 | 1.15 | 0.67 | — | 0.00 | 0.06 |
| Debt / assets | 0.10 | 0.37 | 0.52 | 0.31 | 0.18 | 0.35 | 0.25 | — | 0.00 | 0.04 |
| Net debt / EBITDA | −0.77 | −0.61 | — | — | — | — | — | — | — | — |
| Current ratio | 2.42 | 2.13 | 1.86 | 1.78 | 2.43 | 2.18 | 2.04 | 4.94 | 6.40 | 3.37 |
| Quick ratio | 2.30 | 2.04 | 1.76 | 1.64 | 2.33 | 2.14 | 2.02 | 4.91 | 6.40 | 3.37 |
| Interest coverage | 17.1 | 3.1 | -3.0 | -15.0 | -2.6 | -21.4 | -206.2 | — | — | — |
| Working capital | $140.9M | $71.8M | $46.0M | $50.7M | $90.9M | $48.1M | $60.8M | $109.3M | $99.1M | $53.6M |
| Invested capital | $289.8M | −$14.1M | −$25.0M | −$30.3M | −$64.0M | $15.8M | −$8.0M | −$18.7M | −$14.8M | −$16.3M |
| Tangible asset value | $366.7M | −$23.8M | −$42.5M | −$28.6M | $30.4M | $34.0M | $53.8M | $109.9M | $100.6M | $55.0M |
| Net current asset value | $118.1M | −$25.6M | −$46.6M | −$32.0M | $17.5M | $12.6M | $25.3M | $107.8M | $99.0M | $53.1M |
| Graham number | $95.44 | $2.03 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $4.11 | −$2.78 | −$3.64 | −$3.18 | $0.17 | −$0.37 | $0.75 | $6.40 | $7.70 | $5.47 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $0 | $10.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | 0.0% | 32.2% | — | — | 0.0% | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.2% | 12.8% | 0.4% | 0.4% | 1.2% | 2.5% | 2.5% | 3.7% | 3.9% |
| Capex / operating cash flow | 0.0% | 1.3% | — | — | 10.7% | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.18 | 12.12 | 0.45 | 0.54 | 1.79 | 2.13 | 1.86 | 0.35 | 0.85 |
| Stock-based compensation / revenue | 4.3% | 6.9% | 7.5% | 10.3% | 6.4% | 6.7% | 15.4% | 17.3% | 133.5% | 36.0% |
| R&D / revenue | 11.3% | 13.0% | 21.0% | 50.1% | 43.7% | 55.3% | 89.2% | 105.4% | 1,031.9% | 311.3% |
| SG&A / revenue | 39.4% | 63.1% | 95.0% | 93.5% | 61.6% | 70.5% | 125.8% | 157.3% | 843.7% | 102.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 57.9 | 73.5 | 110.7 | 84.7 | 38.5 | 43.8 | 43.7 | 33.4 | — | — |
| Days of inventory on hand | 162.8 | 112.8 | 375.8 | 1,641.8 | 1,390.9 | 610.1 | 452.8 | 568.5 | — | — |
| Days payables outstanding | 97.9 | 102.6 | 761.1 | 2,744.6 | 1,264.2 | 1,602.5 | 2,123.7 | 5,740.2 | 32.3 | 23.9 |
| Cash conversion cycle (days) | 122.8 | 83.7 | -274.6 | -1,018.1 | 165.2 | -948.6 | -1,627.2 | -5,138.2 | — | — |
| Receivables turnover | 6.30 | 4.97 | 3.30 | 4.31 | 9.49 | 8.33 | 8.36 | 10.92 | — | — |
| Payables turnover | 3.73 | 3.56 | 0.48 | 0.13 | 0.29 | 0.23 | 0.17 | 0.06 | 11.29 | 15.24 |
| Inventory turnover | 2.24 | 3.24 | 0.97 | 0.22 | 0.26 | 0.60 | 0.81 | 0.64 | — | — |
| Asset turnover | 0.87 | 1.28 | 0.93 | 0.80 | 1.07 | 0.84 | 0.41 | 0.34 | 0.05 | 0.19 |
| Average receivables | $46.7M | $36.1M | $35.4M | $27.9M | $15.7M | $13.0M | $7.1M | $4.1M | — | — |
| Average payables | $5.3M | $5.2M | $14.8M | $13.2M | $3.8M | $3.9M | $5.3M | $4.5M | $4.1M | $4.2M |
| Average inventory | $8.8M | $5.8M | $7.3M | $7.9M | $4.1M | $1.5M | $1.1M | $447,000 | $0 | $0 |
| Intangibles / total assets | 4.8% | 16.5% | 11.8% | 11.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from RIGL's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RIGL valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Rigel Pharmaceuticals traded at 2.2 times earnings. Based on the latest twelve months, the trailing P/E is 2.7 and the forward P/E is 9.3. Rigel Pharmaceuticals earned a return on equity of 185.9% and a return on invested capital of 91.0% in fiscal 2025. It ended the year with $53.3 million of debt and $155.0 million in cash and short-term investments, a net cash position of $101.7 million. The share count rose 99.6% from 9.4M to 18.8M over 9 years.
See the RIGL income statement, the RIGL chart for price history, or the RIGL stock overview for the latest quote and news.
RIGL key metrics FAQ
What is Rigel Pharmaceuticals's P/E ratio?
Rigel Pharmaceuticals's trailing P/E ratio is 2.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.3. At the end of fiscal 2025 it was 2.2.
What is Rigel Pharmaceuticals's EV/EBITDA?
Rigel Pharmaceuticals's enterprise value was 5.4 times EBITDA at the end of fiscal 2025 (enterprise value $705.3 million, EBITDA $131.6 million); the current EV/EBITDA is 9.1.
What is Rigel Pharmaceuticals's return on equity?
Rigel Pharmaceuticals's return on equity (ROE) was 185.9% in fiscal 2025: net income of $367.0 million on average shareholders' equity of $197.4 million.
What is Rigel Pharmaceuticals's ROIC?
Rigel Pharmaceuticals's return on invested capital was 91.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals had total debt of $53.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.14 and more cash than debt.
What is Rigel Pharmaceuticals's free cash flow yield?
Rigel Pharmaceuticals generated $75.7 million of free cash flow in fiscal 2025, a free cash flow yield of 9.4% on its market value at year-end ($806.9 million).
What is Rigel Pharmaceuticals's current ratio?
Rigel Pharmaceuticals's current ratio was 2.42 at the end of fiscal 2025: current assets were 2.42 times current liabilities.